Treatment options for patients with severe rheumatoid arthritis are gradually increasing

Drugs and Therapy Perspectives

Volumn 17, Issue 12, 2001, Pages 4-8

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLOROQUINE; CYCLOSPORIN; CYTOKINE; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG TOLERABILITY; HEADACHE; HUMAN; JOINT DESTRUCTION; MONOTHERAPY; NAUSEA AND VOMITING; RHEUMATOID ARTHRITIS; RHINITIS; SKIN MANIFESTATION; STOMATITIS; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION;

EID: 0035908041     PISSN: 11720360     EISSN: None     Source Type: Journal    
DOI: 10.2165/00042310-200117120-00002     Document Type: Article

References (16)

1. Management of the patient with severe refractory rheumatoid arthritis. Are the newer treatment options worth considering?
2. Leflunomide. A review of its use in active rheumatoid arthritis
3. Etanercept. A review of its use in rheumatoid arthritis
4. Infliximab. A review of its use in the management of rheumatoid arthritis
5. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosion at four months after symptom onset
6. Joint erosions and patients with early rheumatoid arthritis
7. Clinical observations often provide more accurate information concerning the long-term natural history and results than structured research studies
8. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventative strategy
9. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
10. Guidelines for the management of rheumatoid arthritis
11. Anti-TNFα therapy and drug induced lupus-like syndrome
12. A trial of Etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
13. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial